|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
SCIDIR_on1105199266 |
| 003 |
OCoLC |
| 005 |
20231120010401.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
190621s2019 enka ob 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d N$T
|d OPELS
|d EBLCP
|d OCLCF
|d UKAHL
|d OCLCQ
|d LVT
|d VT2
|d OCLCO
|d OCLCA
|d YDX
|d OCLCQ
|d OCLCO
|d K6U
|d OCLCQ
|d OCLCO
|
| 019 |
|
|
|a 1229705870
|a 1235827072
|a 1263004235
|
| 020 |
|
|
|a 9780128031643
|q (electronic bk.)
|
| 020 |
|
|
|a 0128031646
|q (electronic bk.)
|
| 020 |
|
|
|a 0128031611
|
| 020 |
|
|
|a 9780128031612
|
| 020 |
|
|
|z 9780128031612
|
| 035 |
|
|
|a (OCoLC)1105199266
|z (OCoLC)1229705870
|z (OCoLC)1235827072
|z (OCoLC)1263004235
|
| 050 |
|
4 |
|a RM315
|
| 060 |
|
4 |
|a W1
|b TE197D v.29 2019
|
| 060 |
|
4 |
|a QV 76.5
|
| 072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 615/.78
|2 23
|
| 245 |
0 |
0 |
|a Translational medicine in CNS drug development /
|c edited by George G. Nomikos and Douglas E. Feltner.
|
| 250 |
|
|
|a First edition.
|
| 264 |
|
1 |
|a London :
|b Academic Press,
|c [2019]
|
| 264 |
|
4 |
|c �2019
|
| 300 |
|
|
|a 1 online resource :
|b color illustrations
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Handbook of behavioral neuroscience ;
|v volume 29
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (EBSCO, viewed June 24, 2019).
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a Translating animal models of obesity and diabetes to the clinic / B.M. Geiger and E.N. Pothos -- Giomarker-guided drug development for better defined early patient studies and clinical trial efficiency / Aldemar Degroot -- Modeling and simulation in the translational pharmacology of CNS drugs / Elizabeth C. De Lange and Peter Bonate -- Functional measurements of central nervous system drug effects in early human drug development / Joop van Gerven -- Experimental medicine approaches in CNS drug development / Jeffrey Paul -- New approaches in translational medicine for Phase I clinical trials of CNS drugs / Matthew Macaluso, Michael Krams, Jonathan Savitz, Wayne C. Drevets, and Sheldon H. Preskorn -- Translational approaches for antidepressant drug development / Gerard J. Marek -- Biomarker opportunities to enrich clinical trial populations for drug development in schizophrenia and depression / Bruce J. Kinon -- PET occupancy and competition in translational medicine and CNS drug development / Paul Cumming and Gerhard Gr|nder -- Stable isotope labeling kinetics in CNS translational medicine : introduction to SILK technology / Randall J. Bateman ... [et. al.] -- Applications of neurophysiological biomarkers in CNS drug development : focus on psychoses / Yash B. Joshi, Melissa A. Tarasenko, and Gregory A. Light -- Heart rate variability as a translational biomarker for emotional and cognitive deficits / Bart A. Ellenbroek, Meyrick Kidwell, Joyce Colussi-Mas, and Jiun Youn -- Drug discovery in psychiatry : time for human genome-guided solutions / Andreas Papassotiropoulos and Dominique J.-F. de Quervain -- Use of cognition to guide decisions about the safety and efficacy of drugs in early-phase clinical trials / Paul Maruff -- Digital biomarkers in clinical drug development / Amir Kalali, Sarah Richerson, Emilia Ouzunova, Ryan Westphal, and Bradley Miller -- Lessons learned from public private partnerships and consortia : the ADNI paradigm / Enchi Liu -- Regulatory perspectives on the use of biomarkers and personalized medicine in CNS drug development : the FDA viewpoint / Mathangi Gopalakrishnan and Jogarao V.S. Gobburu -- Regulatory considerations for the use of biomarkers and personalized medicine in CNS drug development : a European perspective / Eamon O'Loinsigh and Anjana Bose -- Regulatory science objectives and biomarker qualification through public-private partnerships are critical to delivering innovative treatments for CNS diseases / Diane T. Stephenson and Stephen P. Arneri -- The assessment of cognition in translational medicine : a contrast between the approaches used in Alzheimer's disease and major depressive disorder / John E. Harrison and Suzanne Hendrix -- Translational medicine strategies in drug development for neurodevelopmental disorders / Siddharth Srivastava, Mustafa Sahin, and Lisa Prock -- Translational medicine strategies in drug development for mood disorders / Zihang Pan, Radu C. Grovu, and Roger S. McIntyre -- Translational medicine strategies in Alzheimer's disease drug development / Veronika Logovinsky -- Experimental medicine models in generalized anxiety disorder and social anxiety disorder / David S. Baldwin and Ayman Abou-Aisha -- Translational medicine strategies in PTSD drug development / Dan J. Stein, Willie Daniels, and Brian H. Harvey -- Translating neurobiology into practice in tobacco, alcohol, drug, and behavioral addictions / Benjamin Srivastava and Mark S. Gold -- Translational medicine strategies for drug development for impulsive aggression / Emil F. Coccaro, Royce Lee, and Neal G. Simon -- Hypothesizing major depression as a subset of remard deficiency syndrome (RDS) linked to polymorphic reward genes ; considerations for translational medicine approaches for future drug development -- Traveling through the storm : leveraging virtual patient monitoring and artificial intelligence to observe, predict, and affect patient behavior in CNS drug development / Adam Hanina and Laura Shafner.
|
| 650 |
|
0 |
|a Neuropsychopharmacology.
|
| 650 |
|
0 |
|a Drug development.
|
| 650 |
1 |
2 |
|a Central Nervous System Agents
|0 (DNLM)D002491
|
| 650 |
2 |
2 |
|a Drug Development
|0 (DNLM)D000076722
|
| 650 |
2 |
2 |
|a Translational Research, Biomedical
|0 (DNLM)D057170
|
| 650 |
|
6 |
|a Neuropsychopharmacologie.
|0 (CaQQLa)201-0006772
|
| 650 |
|
6 |
|a M�edicaments
|x D�eveloppement.
|0 (CaQQLa)201-0306620
|
| 650 |
|
6 |
|a M�edicaments du syst�eme nerveux central.
|0 (CaQQLa)201-0266419
|
| 650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
| 650 |
|
7 |
|a Drug development
|2 fast
|0 (OCoLC)fst00898670
|
| 650 |
|
7 |
|a Neuropsychopharmacology
|2 fast
|0 (OCoLC)fst01036504
|
| 700 |
1 |
|
|a Nomikos, George G.,
|e editor.
|
| 700 |
1 |
|
|a Feltneruglas E.,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Translational medicine in CNS drug development.
|b First edition.
|d London : Academic Press, [2019]
|z 9780128031612
|z 0128031611
|w (OCoLC)1022775525
|
| 830 |
|
0 |
|a Handbook of behavioral neuroscience ;
|v v. 29.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/handbooks/15697339/29
|z Texto completo
|
